In section Market Quotes

KarXT Improves Alzheimer’s Psychosis Scores in Phase 3 Study

Bristol Myers Squibb said preliminary Phase 3 results show its KarXT treatment improved scores for hallucinations and delusions, as well as overall disease severity, in patients with Alzheimer’s disease. The company released the findings Wednesday while awaiting the study’s full results.

KarXT Improves Alzheimer’s Psychosis Scores in Phase 3 Study

Separate findings on long-term safety and tolerability showed KarXT was generally well tolerated through week 52, with low rates of discontinuation, according to the company. Treatment-emergent adverse events occurred in 65% of participants; serious treatment-emergent adverse events were reported in 7.7%.

Share:on TelegramXFacebook

Subscribe to our newsletter

Once a week — the best stories from our editors, no ads or push notifications. Delivered Sunday morning.

Comments (0)

Leave a comment

No comments yet. Be the first!